George Medicines Partners with Ahngook Pharmaceutical to Commercialize GMRx2 in Korea

Shots:

• George Medicines has entered into an exclusive licensing & supply agreement with Ahngook Pharmaceutical, granting rights to seek regulatory approval & commercialize GMRx2 in Korea for the treatment of Hypertension
• As per the deal, George Medicines will receive an upfront licensing fee, potential regulatory & commercial milestone payments, as well as stepped royalties on sales, while Ahngook will handle regulatory approval & commercialization in Korea
• GMRx2 is a single-pill triple combination therapy containing Telmisartan, Amlodipine, & Indapamide, developed in 3 dose strengths, to deliver early blood pressure reduction with an established antihypertensive safety profile

Ref: Globenewswire | Image: George &  Ahngook | Press Release

Related News: The US FDA Approves George Medicines’ Widaplik for Hypertension in Adults

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com